Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 15, 2014, Pages 6009-6014

  Jin, Congguo ^a   Li, Jia ^a   Wang, Yeying ^a   Chen, Xiaoqun ^a   Che, Yanhua ^b   Liu, Xin ^a   Wang, Xicai ^a   Sriplung, Hutcha ^c  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b First People's Hospital of Kunming   (China)

^c PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

CIK cell; Immune function; Lung cancer; Prognosis

Indexed keywords

ADENOCARCINOMA; BIOLOGICAL THERAPY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL- AND TISSUE-BASED THERAPY; CYTOKINE-INDUCED KILLER CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84906268885     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.15.6009     Document Type: Article

References (20)

1. Blattman JN, Greenberg PD (2004). Cancer immunotherapy: a treatment for the masses. Science, 305, 200-5.
2. Chen W, Zhang R, Zhang S, et al (2013). The incidences and mortalities of major cancers in China, 2009. Chin J Cancer, 32, 106-12.
3. Dougan M, DranoffG (2009). Immune therapy for cancer. Annu Rev Immunol, 27, 83-117.
4. Hontscha C, Borck Y, Zhou H, et al (2011). Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 137, 305-10.
5. Jemal A, Bray F, Melissa M, et al (2011). Global cancer statistics. A Cancer J Clin, 61, 69-90.
6. Jiang J, Xu N, Wu C, et al (2006). Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res, 11, 2237-42.
7. Jiang JT, Shen YP, Wu CP, et al (2010). Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol, 11, 6155-62.
8. Jin CG, Chen XQ, Li J, et al (2013). Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy. Asian Pac J Cancer Prev, 14, 6229-34.
9. Kim HM, Lim J, Park SK, et al (2007). Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol, 7, 1802-7.
10. Li R, Wang C, Liu L, et al (2012). Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother, 61, 2125-33.
11. Lin J, Zhu H, Lu X, et al (2010). Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses. Intern Med, 49, 2341-6.
12. Olioso P, Giancola R, Di Riti M, et al (2009). Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol, 11, 130-9.
13. Schmidt-Wolf IG, Finke S, Trojaneck B, et al (1999). Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer, 11, 1009-16.
14. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al (1993). Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol, 21, 1673-9.
15. Schmidt-Wolf IG, NR, Kiem HP, et al (1991). Use of a SCID mouse/human lymphoma model to evaluate cytokineinduced killer cells with potent antitumor cell activity. J Exp Med, 174, 139-49.
16. Stroncek D, Berlyne D, Fox B, et al (2010). Developments in clinical cell therapy. Cytotherapy, 12, 425-8.
17. Sun Y, Liao M, Cheng G (2011). NCCN nonsmall-cell lung cancer clinical practice guidline:Chinese edition vesion. Beijing.
18. Wu C, Jiang J, Shi L, et al (2008). Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res, 11, 3997-4002.
19. Zheng YW, Li RM, Zhang XW, et al (2013). Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest, 31, 197-205.
20. Zhong R, Han B, Zhong H (2013). A prospective study of the efficacy of a combination of autologous endritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol, [Epub ahead of print].